atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depre...
Atai Beckley N.V - Common Shares (ATAI)
US:NASDAQ Investor Relations:
ir.atai.net.cn
Company Research
Source: GlobeNewswire
Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable antidepressant effects, which are sustained for up to 3 monthsThe second dose of BPL-003 led to further reductions in MADRS scores from baseline, indicating that this regimen has the potential to enhance the clinical response beyond what is observed with a single administrationFindings will be used alongside data from Beckley Psytech’s Phase 2b study of BPL-003 and the soon to be reported Phase 2b open-label extension study to inform the Phase 3 clinical program NEW YORK and AMSTERDAM and OXFORD, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley Psytec
Show less
Read more
Impact Snapshot
Event Time:
ATAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATAI alerts
High impacting Atai Beckley N.V - Common Shares news events
Weekly update
A roundup of the hottest topics
ATAI
News
- H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion [Yahoo! Finance]Yahoo! Finance
- Enhanced Fortifies Executive Leadership Team & Board of DirectorsPR Newswire
- Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato [Yahoo! Finance]Yahoo! Finance
- AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in LondonGlobeNewswire
- ATAI Life Sciences GAAP EPS of -$0.28 misses by $0.17, revenue of $0.75M beats by $0.69M [Seeking Alpha]Seeking Alpha
ATAI
Earnings
- 11/12/25 - Miss
ATAI
Sec Filings
- 12/5/25 - Form 8-K
- 12/5/25 - Form 424B7
- 11/26/25 - Form 4
- ATAI's page on the SEC website